156 451

Cited 4 times in

Ultrashort-acting insulin may improve on 18F-FDG PET/CT image quality in patients with uncontrolled diabetic mellitus.

DC Field Value Language
dc.contributor.authorSong, HS-
dc.contributor.authorYoon, JK-
dc.contributor.authorLee, SJ-
dc.contributor.authorYoon, SH-
dc.contributor.authorJo, KS-
dc.contributor.authorAn, YS-
dc.date.accessioned2014-06-02-
dc.date.available2014-06-02-
dc.date.issued2013-
dc.identifier.issn0143-3636-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/10309-
dc.description.abstractOBJECTIVE: It is known that the poor image quality of (18)F-fluorodeoxyglucose ((18)F-FDG) PET scans leads to interpretation difficulty in patients with uncontrolled diabetes mellitus (DM). We usually delay (18)F-FDG PET examination when patients show high glucose levels. This study was performed to evaluate the usefulness and effects of ultrashort-acting insulin on (18)F-FDG PET/computed tomography (CT) imaging in DM patients.



MATERIALS AND METHODS: A total of 105 DM patients (68 men and 37 women) were included. Ultrashort-acting insulin was intravenously injected when patients showed high glucose levels (>190 mg/dl). (18)F-FDG was injected 60 min after ultrashort-acting insulin injection, and PET/CT images were acquired. Image quality was graded by consensus using the following scale: 1, good; 2, moderate; and 3, poor. The mean standardized uptake value (SUV(mean)) of the liver, gluteal muscle, and brain was assessed to evaluate the effects of ultrashort-acting insulin.



RESULTS: The group administered ultrashort-acting insulin (n=52, blood glucose level: 243.7 ± 46.2 mg/dl) showed a significantly higher glucose level compared with the group not administered ultrashort-acting insulin (n=53, 177.1 ± 5.2 mg/dl). Nevertheless, the image quality of the group with ultrashort-acting insulin was not significantly different from that of the group without ultrashort-acting insulin (χ(2) -test, P=0.47). No significant differences were seen in SUV(mean) in the liver (P=0.13), gluteal muscle (P=0.71), and brain (P=0.16) between groups.



CONCLUSION: Ultrashort-acting insulin can be used to improve the image quality of F-FDG PET/CT in uncontrolled DM patients without significant differences in SUV.
-
dc.language.isoen-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHDiabetes Mellitus/metabolism/*radionuclide imaging/therapy-
dc.subject.MESHFemale-
dc.subject.MESHFluorodeoxyglucose F18/*diagnostic use/pharmacokinetics-
dc.subject.MESHHumans-
dc.subject.MESHInsulin/administration & dosage/*pharmacology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultimodal Imaging/*methods-
dc.subject.MESH*Positron-Emission Tomography-
dc.subject.MESHTime Factors-
dc.subject.MESHTissue Distribution/drug effects-
dc.subject.MESH*Tomography, X-Ray Computed-
dc.subject.MESHTreatment Failure-
dc.titleUltrashort-acting insulin may improve on 18F-FDG PET/CT image quality in patients with uncontrolled diabetic mellitus.-
dc.typeArticle-
dc.identifier.pmid23511925-
dc.identifier.urlhttp://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0143-3636&volume=34&issue=6&spage=527-
dc.contributor.affiliatedAuthor윤, 준기-
dc.contributor.affiliatedAuthor이, 수진-
dc.contributor.affiliatedAuthor안, 영실-
dc.type.localJournal Papers-
dc.identifier.doi10.1097/MNM.0b013e32836066a2-
dc.citation.titleNuclear medicine communications-
dc.citation.volume34-
dc.citation.number6-
dc.citation.date2013-
dc.citation.startPage527-
dc.citation.endPage532-
dc.identifier.bibliographicCitationNuclear medicine communications, 34(6):527-532, 2013-
dc.identifier.eissn1473-5628-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Nuclear Medicine & Molecular Imaging
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse